Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 13;14(10):1232-1244.
doi: 10.7150/ijbs.24612. eCollection 2018.

Review of Drug Repositioning Approaches and Resources

Hanqing Xue  1 , Jie Li  1 , Haozhe Xie  1 , Yadong Wang  1
Affiliations
Review

Review of Drug Repositioning Approaches and Resources

Hanqing Xue et al. Int J Biol Sci. .

Abstract

Drug discovery is a time-consuming, high-investment, and high-risk process in traditional drug development. Drug repositioning has become a popular strategy in recent years. Different from traditional drug development strategies, the strategy is efficient, economical and riskless. There are usually three kinds of approaches: computational approaches, biological experimental approaches, and mixed approaches, all of which are widely used in drug repositioning. In this paper, we reviewed computational approaches and highlighted their characteristics to provide references for researchers to develop more powerful approaches. At the same time, the important findings obtained using these approaches are listed. Furthermore, we summarized 76 important resources about drug repositioning. Finally, challenges and opportunities in drug repositioning are discussed from multiple perspectives, including technology, commercial models, patents and investment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
The investment in drug development by PhRMA member companies and the number of approved drugs by the FDA from 1995 to 2015.
Figure 2
Figure 2
The contrast of traditional drug development and drug repositioning. A) Flowchart of the traditional drug development process. B) Flowchart of drug repositioning.
Figure 2
Figure 2
The contrast of traditional drug development and drug repositioning. A) Flowchart of the traditional drug development process. B) Flowchart of drug repositioning.
Figure 3
Figure 3
Risk and reward in two different drug development strategies
Figure 4
Figure 4
The workflow of text mining.
Figure 5
Figure 5
The workflow of a semantic network inference.
See this image and copyright information in PMC

References

    1. Sertkaya A, Birkenbach A, Berlind A, Eyraud J. Examination of clinical trial costs and barriers for drug development. US Department of health and human services, office of the assistant secretary for planning and evaluation report. 2014;1:1–92.
    1. Yeu Y, Yoon Y, Park S. Protein localization vector propagation: a method for improving the accuracy of drug repositioning. Mol Biosyst. 2015;11(7):2096–102. - PubMed
    1. Pharmaceutical Research and Manufacturers of America. http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf.2015.
    1. Drug development process. https://www.fda.gov/Drugs/default.htm.
    1. Drug approval process. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm.

Publication types

LinkOut - more resources